Fatty Liver Disease: MASH (formerly known as NASH) - Yale Medicine Explains

MASH Explained: Why the Name Changed and Why You Should Care

If you've been hearing the term "MASH" and wondering what happened to "NASH," this video from Yale Medicine clears it up. The condition formerly known as non-alcoholic steatohepatitis (NASH) has been renamed metabolic dysfunction-associated steatohepatitis (MASH). The rename isn't just cosmetic. It reflects a fundamental shift in how the medical community understands fatty liver disease: it's driven by metabolic dysfunction, not simply the absence of alcohol.

Yale Medicine does a clean job laying out the progression of liver disease. It starts with simple steatosis, which is fat accumulation in the liver. About 30% of adults in the US have this to some degree. For most people, it's benign. But in a subset, the fat triggers inflammation and liver cell damage, which is when you cross into MASH territory. From there, the liver can progress to fibrosis (scarring), cirrhosis (severe scarring that impairs liver function), and eventually liver failure or liver cancer.

The video emphasizes that MASH is largely a silent disease. Most people with it have no symptoms until significant damage has occurred. Liver enzymes on a standard blood panel can be normal even when the liver is inflamed. This is why screening with more sensitive tools, like a FibroScan (transient elastography) or specific blood biomarker panels, matters for people at risk.

The Metabolic Connection That Ties Everything Together

Here's what makes this relevant to the GLP-1 conversation. The metabolic dysfunction that drives MASH is the same cluster of problems that GLP-1 drugs address: insulin resistance, visceral adiposity, systemic inflammation, and dyslipidemia. You don't get MASH because your liver decided to start collecting fat. You get it because your metabolic system is sending the wrong signals, and the liver is caught in the crossfire.

Insulin resistance is the primary driver. When cells become resistant to insulin, the body produces more insulin to compensate. High insulin levels promote fat storage, including in the liver. That hepatic fat then becomes a source of local inflammation, which damages liver cells and triggers the fibrotic cascade. Breaking this cycle by improving insulin sensitivity is the most effective strategy for treating MASH, and it's exactly what GLP-1 drugs do.

The video discusses the lack of FDA-approved treatments for MASH historically, noting that resmetirom (brand name Rezdiffra) was the first drug approved specifically for this condition in 2024. But GLP-1 drugs, while not specifically approved for MASH, have shown impressive results in clinical trials for reducing liver fat, resolving steatohepatitis, and in some cases improving fibrosis.

What the Video Gets Right

The explanation of disease progression is excellent and easy to follow. Using a staircase analogy from simple fat to inflammation to scarring to cirrhosis gives viewers a mental model that's clinically accurate. The emphasis on screening in at-risk populations is an important public health message that many liver disease videos skip.

What the Video Doesn't Cover

This is a liver disease overview, not a GLP-1 video, so the connection to GLP-1 drugs isn't explored in depth. Viewers who found this video through a search related to Ozempic and fatty liver will need to look elsewhere for specific trial data on semaglutide for MASH. The video also doesn't discuss the practical question of how often at-risk patients should be screened, or what threshold of fibrosis warrants aggressive treatment.

Questions for Your Doctor

If you have risk factors for fatty liver disease (obesity, type 2 diabetes, metabolic syndrome, PCOS), here are some conversation starters:

Ask for a screening beyond standard liver enzymes. A FibroScan or the FIB-4 index (calculated from routine blood work) can detect liver fibrosis before symptoms appear. Ask what your liver fat fraction is. If you've had an abdominal MRI or ultrasound for any reason, fat fraction may have been measured or can be estimated. Ask whether your metabolic profile puts you at risk. Fasting insulin, HbA1c, triglycerides, and waist circumference all help quantify your MASH risk.

Ask about GLP-1 drugs if you're already a candidate based on weight or diabetes. The liver benefits may be an added reason to start treatment. And ask about follow-up imaging. If you're diagnosed with fatty liver, knowing how often to recheck is important for tracking whether your interventions are working.

The Progression From Fat to Fibrosis: What Drives It

Understanding why some people with fatty liver progress to MASH while others don't is one of the most active areas of hepatology research. The "two-hit" hypothesis has been updated to a "multiple parallel hits" model. The first hit is fat accumulation, driven by insulin resistance. But progression to inflammation requires additional insults: oxidative stress from mitochondrial dysfunction, endoplasmic reticulum stress from overwhelmed protein processing, gut-derived endotoxins crossing a leaky intestinal barrier, and genetic susceptibility factors like the PNPLA3 variant that affects lipid handling in liver cells. When multiple hits converge, the liver transitions from benign steatosis to active steatohepatitis.

The fibrosis that follows is the body's attempt to heal the ongoing injury. Hepatic stellate cells, which normally sit quietly in the liver, become activated by inflammatory signals and start producing collagen. In small amounts, this is a normal wound-healing response. But when inflammation persists, collagen accumulates faster than it can be remodeled, leading to progressive fibrosis. The fibrosis stages (F0 through F4) represent increasing amounts of collagen deposition, with F4 (cirrhosis) representing such extensive scarring that the liver's architecture is permanently distorted, impairing blood flow and function. The transition from F2 to F3 is often considered the tipping point beyond which progression to cirrhosis becomes much more likely, making early detection and intervention at F2 or below particularly important.

What GLP-1 Drugs Specifically Do for the Liver

GLP-1 receptor agonists address several of the "hits" that drive MASH progression. By improving insulin sensitivity, they reduce the primary driver of hepatic fat accumulation. By reducing systemic inflammation and C-reactive protein levels, they lower the inflammatory burden on the liver. By promoting weight loss, they reduce the amount of visceral fat that produces the inflammatory cytokines contributing to hepatic damage. And there's emerging evidence that GLP-1 receptors on hepatocytes may directly influence intracellular lipid metabolism, meaning the drug has effects on the liver beyond what systemic metabolic improvement alone would predict.

The clinical trial data supports this multi-pathway mechanism. In the Phase 2 semaglutide trial for MASH, 59% of patients achieved steatohepatitis resolution on liver biopsy, compared to 17% on placebo. Liver fat content decreased dramatically, and biomarkers of hepatocyte injury (like ALT) normalized in many patients. What's particularly notable is that the fibrosis improvement, while more modest than the steatohepatitis resolution, trended in the right direction. Fibrosis takes longer to reverse than inflammation, so longer trials may show more impressive fibrosis results. The Phase 3 trials for semaglutide in MASH are ongoing and will provide the data needed for a potential FDA approval for this specific indication.

The Alcohol Interaction Question

One topic the video doesn't address but is relevant for many patients is the interaction between alcohol consumption and fatty liver disease. The old distinction between "alcoholic" and "non-alcoholic" fatty liver was always a bit artificial, because many patients have both metabolic and alcohol-related contributions to their liver disease. Even moderate alcohol consumption can exacerbate metabolic liver damage in someone with insulin resistance. For patients starting GLP-1 drugs for weight management or diabetes who also drink regularly, understanding that alcohol adds to their liver's burden is an important conversation to have with their doctor. Reducing or eliminating alcohol while on GLP-1 therapy may enhance the liver benefits of the medication.

Who Is at Risk and When to Get Screened

The risk factors for MASH line up almost perfectly with metabolic syndrome: central obesity (waist circumference above 35 inches for women or 40 inches for men), elevated fasting glucose or diagnosed type 2 diabetes, high triglycerides, low HDL cholesterol, and elevated blood pressure. If you have three or more of these, your probability of having some degree of fatty liver disease exceeds 50%. PCOS (polycystic ovary syndrome) is another strong risk factor, as the insulin resistance that drives PCOS also drives hepatic fat accumulation. Certain ethnicities, particularly Hispanic populations, have higher genetic susceptibility due to prevalence of the PNPLA3 risk variant.

Screening should happen at the primary care level, not after referral to a specialist. The practical screening pathway is straightforward: calculate a FIB-4 score from routine bloodwork (age, AST, ALT, platelets). If the score is below 1.3, the risk of significant fibrosis is low, and repeat screening in 2-3 years is reasonable. If the score is between 1.3 and 2.67, consider a FibroScan or referral to hepatology for further evaluation. If the score is above 2.67, hepatology referral is strongly recommended because significant fibrosis is likely. This algorithmic approach costs almost nothing to implement and could prevent thousands of cases of advanced liver disease annually if adopted widely. The barriers aren't scientific or economic. They're about awareness and clinical inertia, which is exactly the kind of gap that patient advocacy and education can help close.

Who Should Watch This

Anyone with metabolic syndrome, type 2 diabetes, or obesity should watch this video to understand their liver risk. It's especially relevant if you've been told you have a "fatty liver" on an ultrasound and your doctor didn't elaborate on what that means or what to do about it. Healthcare providers who are new to the NASH-to-MASH naming transition will also find this a useful refresher on the updated terminology and diagnostic criteria.